

UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL  
ESCOLA DE EDUCAÇÃO FÍSICA, FISIOTERAPIA E DANÇA

**Felipe Colmeneiro dos Santos**

**REPRODUTIBILIDADE DO TESTE DE SENTAR E LEVANTAR CINCO VEZES  
EXECUTADO REMOTAMENTE POR PACIENTES COM ESCLEROSE MÚLTIPLA**

Porto alegre

2022

**Felipe Colmeneiro dos Santos**

**REPRODUTIBILIDADE DO TESTE DE SENTAR E LEVANTAR CINCO VEZES  
EXECUTADO REMOTAMENTE POR PACIENTES COM ESCLEROSE MÚLTIPLA**

Trabalho de Conclusão de Curso  
apresentado como requisito parcial para  
obtenção do grau de bacharel em  
Fisioterapia.

Orientador: Prof. Dr. Luciano Palmeiro Rodrigues  
Co-orientadora: Profa. Dra. Cláudia Tarragô Candotti

Porto Alegre

2022

## RESUMO

Conhecida como a principal causa da incapacidade neurológica não traumática em adultos jovens, a Esclerose Múltipla causa alteração de força muscular, principalmente em Membros Inferiores. A avaliação de força muscular nestes pacientes é imprescindível e pode ser realizada através do Teste de Sentar e Levantar de Cinco Vezes, que comumente é realizado de forma presencial. A partir da pandemia do COVID-19, os fisioterapeutas iniciaram a realização de atendimentos remotos, amparados pela Resolução nº 516/2020 (COFFITO, 2020), a qual permitiu os teleatendimentos no Brasil, criando a necessidade dos fisioterapeutas de realizarem avaliações de forma remota, ao invés de presencial, mesmo sem evidências da confiabilidade de alguns testes, como o Teste de Sentar e Levantar de Cinco Vezes, executado remotamente. Nesse contexto, o objetivo desse estudo foi avaliar a reprodutibilidade intra-avaliador e inter-avaliador do Teste de Sentar e Levantar de Cinco Vezes de maneira remota e síncrona, em pacientes com Esclerose Múltipla para avaliação dos Membros Inferiores. A amostra foi composta por 33 indivíduos com Esclerose Múltipla do tipo surto-remissão (18 femininos e 15 masculinos;  $43,7 \pm 13,4$  anos). As avaliações ocorreram de forma remota e síncrona através de aplicativo de mensagens, por vídeo-chamada. Para avaliar a reprodutibilidade inter-avaliador foi verificado o tempo de execução do Teste de Sentar e Levantar de Cinco Vezes, em segundos, na mesma vídeo-chamada, por dois avaliadores diferentes. Para a avaliação da reprodutibilidade intra-avaliador foram realizadas duas vídeo-chamadas diferentes, pelo mesmo avaliador, com intervalo de 24 a 28 horas. Os dados foram analisados no software SPSS 20.0 por meio de estatística descritiva e inferencial. No que diz respeito à estatística descritiva, foram calculadas médias e desvio padrão. Para análise inferencial da reprodutibilidade intra e interavaliador, foi utilizado o coeficiente de correlação intraclassa (ICC), com o nível de significância de 0,05, o erro padrão de medida (SEM) e a mínima mudança detectável (MDC). Foram encontrados excelentes valores de ICC e baixos valores de SEM e MDC na reprodutibilidade inter-avaliador (ICC: 0,993 (0,986-0,996); valor p:  $<0,001$ ; SEM: 0,6s; MDC: 1,6s) e intra-avaliador (ICC: 0,962 (0,925-0,981); valor p:  $<0,001$ ; SEM: 1,4s; MDC: 3,8s). A partir desses valores, considera-se que o Teste de Sentar e Levantar de Cinco Vezes, executado de forma remota e síncrona, em pacientes com Esclerose Múltipla

do tipo surto-remissão, é confiável e reprodutível, podendo ser utilizado tanto por diferentes avaliadores, em serviços prestadores de avaliação, quanto pelo mesmo avaliador, em situações de pré e pós-teste, por exemplo.

Palavras-chave: esclerose múltipla; força muscular; telemonitoramento; telerreabilitação; reprodutibilidade dos testes.

## ABSTRACT

Recognized as the main cause of non-traumatic neurological disability in young adults, Multiple Sclerosis causes inclusion of muscle strength, mainly in the lower limbs. Muscle strength in these patients is essential and can be performed through the Five Times Test, which is commonly performed in person. From the COVID-19 pandemic, physical therapists started to carry out remote consultations, supported by n° 516/2020 (COFFITO, 2020), a need to qualify teleservices in Brazil, creating remote physical therapy assistance, instead of face-to-face, even without proof of test reliability, such as Testing and Surveying Five times, proven from some tests. In this context, the aim of this study was to evaluate the intra-rater and inter-rater reproducibility of the Five Times Sit-Up Test remotely and synchronously, in patients with Multiple Sclerosis to assess the Relapse-remitting multiple (18 females and 15 males;  $43.7 \pm 13.4$  years). Remote consultation instructions and the messaging app, by video call. To evaluate the inter-evaluator reproducibility, the time of execution of the Sitting and Standing Five Times, in seconds, in the same video call, by two different evaluators was selected. For the evaluation of intra-evaluator reproducibility, two different calls were made by the same evaluator video, with an interval of 24 to 28 hours. Data were analyzed in SPSS 20.0 software using descriptive and inferential statistics. With regard to descriptive statistics, means and standard deviations were observed. For intra- and inter-assessment reproducibility analysis, the intraclass assessment test (ICC) was used, with a significance level of 0.05, standard error of measurement (SEM) and minimum detectable change (MDC). Excellent ICC values and low SEM and MDC values were found after inter-rater reproducibility (ICC: 0.993 (0.986-0.996); p-value: <0.001; SEM: 0.6s; MDC: 1.6s) and intra-rater (ICC: 0.962 (0.925-0.981); p-value: <0.001; SEM: 1.4s; MDC: 3.8s). Based on these values, it is considered that the Five Times Sit-Up Test, performed remotely and synchronously, in patients with assessment services services, in pre- and post-test situations, for example assessment.

Keywords: multiple sclerosis; muscle strength; telemonitoring; grower rehabilitation; test reproducibility.

## SUMÁRIO

<b>1</b>	<b>APRESENTAÇÃO</b>	<b>8</b>
<b>2</b>	<b>ARTIGO COMPLETO</b>	<b>9</b>
2.1	INTRODUÇÃO	10
2.2	MÉTODOS	12
2.3	RESULTADOS	15
2.4	DISCUSSÃO	17
2.5	CONCLUSÃO	21
2.6	REFERÊNCIAS	21
<b>3</b>	<b>ANEXOS</b>	<b>24</b>
3.1	ANEXO A – Normas da revista Multiple Sclerosis and Related Disorders	24
<b>3.1.1</b>	<b>Description</b>	<b>24</b>
<b>3.1.2</b>	<b>Audience</b>	<b>24</b>
<b>3.1.3</b>	<b>Guide for authors</b>	<b>25</b>
3.1.3.1	Introduction	25
3.1.3.1.1	Types of article	25
3.1.3.1.2	Contact details for submission	26
3.1.3.1.3	Submission checklist	26
3.1.3.2	Before you begin	27
3.1.3.2.1	Ethics in publishing	27
3.1.3.2.2	Studies in humans and animals	27
3.1.3.2.3	Informed consent and patient details	28
3.1.3.2.4	Declaration of interest	29
3.1.3.2.5	Submission declaration and verification	29
3.1.3.2.6	Use of inclusive language	29
3.1.3.2.7	Author contributions	30
3.1.3.2.8	Changes to authorship	30
3.1.3.2.9	Clinical trial results	31
3.1.3.2.10	Copyright	32
3.1.3.2.11	Role of the funding source	33

3.1.3.2.12	Open access.....	33
3.1.3.2.13	Submission .....	34
3.1.3.3	Preparation .....	34
3.1.3.3.1	Queries .....	34
3.1.3.3.2	New submissions .....	34
3.1.3.3.3	Peer review .....	35
3.1.3.3.4	Revised submissions.....	36
3.1.3.3.5	Article structure.....	36
3.1.3.3.6	Essential title page information .....	37
3.1.3.3.7	Highlights.....	38
3.1.3.3.8	Abstract.....	38
3.1.3.3.9	Keywords.....	39
3.1.3.3.10	Artwork.....	41
3.1.3.3.11	Tables .....	42
3.1.3.3.12	References.....	43
3.1.3.3.13	Video.....	46
3.1.3.3.14	Data visualization.....	48
3.1.3.3.15	Supplementary material .....	48
3.1.3.3.16	Research data .....	48
3.1.3.4	After acceptance.....	50
3.1.3.4.1	Online proof correction.....	50
3.1.3.4.2	Offprints .....	51
3.1.3.5	Author inquiries .....	51

## **1 APRESENTAÇÃO**

O presente estudo foi elaborado nos anos de 2020 e 2021, pois com a pandemia da COVID-19, os acompanhamentos fisioterapêuticos do grupo de caminhada, do projeto de extensão “Orientação de caminhada e exercícios para portadores de Esclerose Múltipla”, coordenado pelo professor Luciano Palmeiro, do qual faço parte, tiveram que continuar. Entretanto, no presente momento, até onde tenho conhecimento, a comunidade científica ainda carece de informações quanto a confiabilidade das tradicionais escalas e testes de forma remota. Essa realidade afeta diretamente os atendimentos fisioterapêuticos e pesquisas que precisam avaliar o efeito de uma intervenção remota. Foi nesse contexto que surgiu a ideia e a motivação para desenvolver essa pesquisa.

O artigo está formatado nas normas da revista na qual será submetido, a revista *Multiple Sclerosis and Related Disorders* (Fator de Impacto 4,3; Qualis: B1). As normas da revista encontram-se no ANEXO A.



## 2 ARTIGO COMPLETO

### **Reprodutibilidade do ‘Teste de Sentar e Levantar Cinco Vezes’ executado remotamente por pacientes com Esclerose Múltipla**

Felipe Colmeneiro dos Santos <sup>a</sup>, Cláudia Tarragô Candotti <sup>b</sup>, Luciano Palmeiro Rodrigues <sup>c</sup>

<sup>a</sup> Discente do Curso de Fisioterapia da Universidade Federal do Rio Grande do Sul. Escola de Educação Física, Fisioterapia e Dança. Rua Felizardo, 750. Bairro Jardim Botânico. Porto Alegre/ RS – Brasil – CEP 90690-200.

<sup>b</sup> Docente do Curso de Fisioterapia da Universidade Federal do Rio Grande do Sul. Escola de Educação Física, Fisioterapia e Dança. Rua Felizardo, 750. Bairro Jardim Botânico. Porto Alegre/ RS – Brasil – CEP 90690-200.

Autor correspondente: [lucianopalmeiro@gmail.com](mailto:lucianopalmeiro@gmail.com) (Luciano Palmeiro Rodrigues)

Contagem eletrônica do total de palavras: 3493

#### **RESUMO**

**Introdução.** Conhecida como a principal causa da incapacidade neurológica não traumática em adultos jovens, a Esclerose Múltipla causa alteração de força muscular, principalmente em Membros Inferiores. A avaliação de força muscular nestes pacientes é imprescindível e pode ser realizada através do Teste de Sentar e Levantar de Cinco Vezes, que comumente é realizado de forma presencial. A partir da pandemia do COVID-19, os fisioterapeutas iniciaram a realização de atendimentos remotos, amparados pela Resolução nº 516/2020 (COFFITO, 2020), a qual permitiu os teleatendimentos no Brasil, criando a necessidade dos fisioterapeutas de realizarem avaliações de forma remota, ao invés de presencial, mesmo sem evidências da confiabilidade de alguns testes, como o Teste de Sentar e Levantar de Cinco Vezes. Nesse contexto, o objetivo desse estudo foi avaliar a reprodutibilidade intra-avaliador e inter-avaliador do TSLCV de maneira remota e

síncrona, em pacientes com Esclerose Múltipla. **Métodos.** A amostra foi composta por 33 indivíduos com Esclerose Múltipla do tipo surto-remissão (18 femininos e 15 masculinos;  $43,7 \pm 13,4$  anos). As avaliações ocorreram de forma remota e síncrona através de aplicativo de mensagens, por vídeo-chamada. Para avaliar a reprodutibilidade inter-avaliador foi verificado o tempo de execução do Teste de Sentar e Levantar de Cinco Vezes, em segundos, na mesma vídeo-chamada, por dois avaliadores diferentes. Para a avaliação da reprodutibilidade intra-avaliador foram realizadas duas vídeo-chamadas diferentes, pelo mesmo avaliador, com intervalo de 24 a 28 horas. Os dados foram analisados no software SPSS 20.0 por meio de estatística descritiva e inferencial. No que diz respeito à estatística descritiva, foram calculadas médias e desvio padrão. Para análise inferencial da reprodutibilidade intra e interavaliador, foi utilizado o coeficiente de correlação intraclassa (ICC), com o nível de significância de 0,05, o erro padrão de medida (SEM) e a mínima mudança detectável (MDC). **Resultados.** Foram encontrados excelentes valores de ICC e baixos valores de SEM e MDC na reprodutibilidade inter-avaliador (ICC: 0,993 (0,986-0,996); valor p:  $<0,001$ ; SEM: 0,6s; MDC: 1,6s) e intra-avaliador (ICC: 0,962 (0,925-0,981); valor p:  $<0,001$ ; SEM: 1,4s; MDC: 3,8s). **Conclusão.** A partir desses valores, considera-se que o Teste de Sentar e Levantar de Cinco Vezes, executado de forma remota e síncrona, em pacientes com Esclerose Múltipla do tipo surto-remissão, é confiável e reprodutível, podendo ser utilizado tanto por diferentes avaliadores, em serviços prestadores de avaliação, quanto pelo mesmo avaliador, em situações de pré e pós-teste, por exemplo.

Palavras-chave: esclerose múltipla; força muscular; telemonitoramento; telerreabilitação; reprodutibilidade dos testes.

## 2.1 INTRODUÇÃO

A Esclerose Múltipla (EM) é considerada a principal causa de incapacidade neurológica não traumática de adultos jovens (Browne et al., 2014; Walton et al., 2020). Entre os tipos de EM, a surto-remissão (SR) é a forma mais comum (85% dos casos) (Multiple Sclerosis International Federation, 2013). A força muscular é prejudicada nos pacientes com EM, sendo esse fato mais evidente quando se

solicita uma contração muscular concêntrica rápida, principalmente nos Membros Inferiores (Msls) (Jørgensen et al., 2017).

A força muscular dos Msls pode ser mensurada através do Teste de Sentar e Levantar (Silva et al., 2014), que foi elaborado por Csuka & McCarty (1985) e passou por algumas alterações, até culminar no Teste de Sentar e Levantar de Cinco Vezes (TSLCV). Durante a execução do TSLCV os músculos mais ativados, medidos através da ativação muscular média, são tibial anterior e vasto medial do quadríceps, com destaque para reto femoral e solear (Roldán-Jiménez et al., 2015).

Na literatura, além de ocorrer divergência entre as alturas dos assentos, variando desde 43 cm até 46 cm (Kim et al., 2010; Møller et al., 2012; Roldán-Jiménez et al., 2015), também não há consenso sobre o posicionamento dos braços durante a execução do teste. No entanto, há relação significativa entre a altura do assento e o tempo de execução do TSLCV (Ng et al., 2015), e já foi documentado que não há diferença no resultado do teste quando comparado braços cruzados e mãos apoiadas nas coxas (Ng et al., 2013). Assim para realizar um teste confiável, recomenda-se utilizar as mesmas instruções ao repetir o TSLCV com o mesmo paciente (Ng et al., 2015).

No que se refere a confiabilidade do TSLCV, existem evidências de que o teste apresenta alta reprodutibilidade intra e inter-avaliador, quando realizado em paciente com Acidente Vascular Cerebral (AVC) crônico (Mong et al., 2010), com Doença de Parkinson (DP) (Duncan et al., 2011), com dor lombar (Simmonds et al., 1998), em idosos saudáveis (Wallmann et al., 2013) e com EM (Møller et al., 2012).

Devido a pandemia do COVID-19, uma das medidas adotadas para barrar o contágio, foi o isolamento social, medida essa que afetou a vida da população em geral (Chen et al., 2020). Por conta dessa situação, os fisioterapeutas tiveram que realizar atendimentos remotos, amparados pela Resolução nº 516/2020 (BRASIL, 2020), a qual permitiu os teleatendimentos no Brasil a partir de Março de 2020 (Carvalho et al., 2020). Assim, nesse contexto de isolamento social, onde a participação em atividades físicas tendeu a diminuir, e visto que a EM impacta diretamente na redução de força muscular nos Msls, a qual pode reduzir ainda mais com a restrição dos pacientes aos seus domicílios, surgiu a necessidade dos fisioterapeutas de avaliar de forma remota a força muscular de Msls.

Não obstante, até onde se tem conhecimento, o tradicional teste TSLCV usado na prática clínica junto aos pacientes com EM, não possui evidências de confiabilidade quando realizado de forma remota. Portanto, o objetivo desse estudo foi avaliar a reprodutibilidade intra-avaliador e inter-avaliador do TSLCV de maneira remota e síncrona, em pacientes com EM, para avaliação da força muscular dos Msls.

## 2.2 MÉTODOS

O estudo observacional de confiabilidade, tem delineamento correlacional. A população foi composta por pessoas com EM do tipo SR do estado do Rio Grande do Sul, Brasil. A captação amostral ocorreu na Associação Gaúcha dos Portadores de Esclerose Múltipla (AGAPEM) e junto aos participantes dos projetos de extensão vinculados ao Programa de Reabilitação e Fisioterapia Neurofuncional (REAFIN) do Hospital de Clínicas de Porto Alegre (HCPA).

O cálculo amostral baseou-se no estudo de Walter *et al.* (1998). Para reprodutibilidade inter-avaliador (2 avaliadores) e intra-avaliador (2 avaliações) foi utilizado um nível de significância de 5%, poder de 80%, hipótese nula de ICC de 0,4, levando em consideração que cada indivíduo seria avaliado duas vezes, esperando encontrar um ICC de 0,7, resultando em uma amostra de 33 indivíduos com EM.

Foram incluídos no estudo, pacientes com diagnóstico de EM do tipo SR. Os pacientes classificados com grau 0 na *Functional Ambulation Category* (FAC); classificados pela Escala Expandida do Estado de Incapacidade de Kurtzke (EDSS) com uma graduação superior a 7,0; os que não realizaram alguma das duas avaliações e os pacientes com alguma alteração musculoesquelética em membros inferiores que interferisse na realização do TSLCV foram excluídos do estudo.

As avaliações foram realizadas apenas após a aprovação do Comitê de Ética e Pesquisa da Universidade Federal do Rio Grande do Sul (UFRGS) (CAAE 57285421.4.0000.5347). Foram respeitadas todas as diretrizes da resolução nº 466/2012 do Conselho Nacional de Saúde sobre ética em pesquisa com seres humanos.

Os pacientes que demonstraram interesse em participar da pesquisa receberam um *link* disponibilizando um formulário do tipo *Google Forms*, contendo:

(1) Termo de Consentimento Livre e Esclarecido (TCLE); (2) breve anamnese; (3) Índice de Barthel (Barros et al., 2009); (4) Escala de Severidade de Fadiga (Toledo et al., 2011); (5) FAC (Elord et al., 2020).

Após o envio dessas informações pelo paciente, era agendada a avaliação remota individual para realização do TSLCV, que ocorreria em dois dias distintos, através de vídeo-chamadas. Para a avaliação remota, dois avaliadores independentes e cegados entre si quanto aos resultados do teste, foram responsáveis por realizar o teste TSLCV: o avaliador 1 (A1) e o avaliador 2 (A2).

Inicialmente era solicitado ao paciente que selecionasse uma cadeira sem braços da sua residência para a realização do teste. Em seguida, era solicitado ao paciente que mensurasse a altura do assento dessa cadeira em relação ao solo. Esta medição era necessária para verificar se a cadeira atendia as especificações para o teste (entre 42 e 46cm de altura em relação ao solo).

Um terceiro pesquisador recebeu os resultados das avaliações imediatamente após o término delas, para organizá-los em planilhas. Com esse procedimento garantiu-se o cegamento entre avaliadores, pois evitou-se que os avaliadores A1 e A2 tivessem qualquer contato com o resultado das avaliações.

As vídeo-chamadas para as avaliações foram realizadas pelo aplicativo de mensagens "*WhatsApp*". A primeira vídeo-chamada foi realizada com a presença dos avaliadores A1, A2 e do paciente. A segunda vídeo-chamada teve a presença apenas do A1 e do paciente e, foi realizada dentro de um intervalo de 24 e 28 horas em relação a primeira vídeo-chamada.

Em ambas vídeo-chamadas, o A1 leu as instruções (Quadro 1) para a realização do teste, e perguntou se havia alguma dúvida a respeito da execução do teste. Após o comando (1, 2, 3, já), o paciente executava o TSLCV pela primeira vez para familiarizar-se. Foi ressaltado que nessa familiarização o paciente não necessitava realizar o teste na maior velocidade para não gerar esforço e interferir na avaliação subsequente. Não houve contagem do tempo na familiarização. Após um intervalo de 1 minuto da familiarização, o A1 dava um novo comando para que o paciente realizasse o TSLCV de forma definitiva. Nesse momento não houve necessidade de nova leitura da instrução.

Para realizar o teste, você iniciará sentado e vai realizar o ato de levantar e sentar da cadeira 5 vezes, terminado o teste sentado. Durante a execução, você irá esticar bem os joelhos ao ficar em pé, e ao sentar transferir bem o peso para a cadeira, de maneira controlada, ou seja, não se jogue. Realize o teste o mais rápido possível, e não retire o pé do chão com o intuito de se embalar. Não utilize os braços para a execução do teste, assim recomendo cruzar os braços à frente do peito.

Para mensurar o tempo de execução, tanto A1 quanto A2, utilizavam um cronômetro online (<http://cronometronline.com.br/>). O cronometro era iniciado ao comando do A1 (1, 2, 3, já). Cada avaliador (A1 e A2) deveria parar o cronometro quando o paciente sentava pela quinta e última vez na cadeira, durante a primeira vídeo-chamada.

Na segunda vídeo-chamada, o A1 lia novamente a mesma instrução de realização do teste, antes que o paciente realizasse o TSLCV. Nessa segunda vídeo-chamada não foi realizada familiarização, pressupondo que o paciente já estava familiarizado com o teste. O comando (1, 2, 3, já) para o início do teste foi dado pelo A1, que também cronometrava o tempo de execução do teste.

Por questões éticas, ao final da segunda vídeo-chamada, os pacientes, que não possuíam acompanhamento fisioterapêutico, receberam um folder com orientações para realizar exercícios físicos, conforme o resultado do TSLCV, como benefício de participar da pesquisa. Com isso, os pacientes que apresentaram fraqueza muscular de Msls receberam orientações de exercícios de força e de alongamentos, enquanto os pacientes que não apresentaram alteração no teste receberam orientação de prática de atividades aeróbicas, visando manter o bom condicionamento.

Os dados coletados nos questionários e os tempos de execução do TSLCV cronometrados pelos A1 e A2, obtidos nos dois momentos de avaliação, foram tabulados no Software Microsoft Excel para análise estatística. A análise estatística foi realizada pelo Software SPSS 20.0 utilizando os procedimentos de estatística descritiva (através de porcentagem, média, moda, mediana e desvio padrão) e inferencial. Em todas as análises foi utilizado o nível de significância de 0,05.

Para comparar os dados obtidos entre os avaliadores e os dados obtidos pelo mesmo avaliador em momentos diferentes foi realizado o teste *T de student* independente e pareado, respectivamente.

Para análise da confiabilidade do TSLCV executado de forma remota, avaliou-se: (1) a reprodutibilidade intra-avaliador, dada pela concordância dos tempos cronometrados pelo A1, obtidos no primeiro e segundo dia de avaliação; e (2) a reprodutibilidade interavaliador, dada pela concordância dos tempos cronometrados pelo A1 e A2, obtidos no primeiro dia de avaliação. Portanto, a fim de avaliar a reprodutibilidade intra e inter-avaliador do TSLCV foi utilizado o Índice de Correlação Intraclasse (ICC) de modelo misto de duas vias, a partir de medidas únicas, para verificar a concordância absoluta (ICC<sub>2,1</sub>) (Koo and Li, 2016; Shrout e Fleiss, 1979). Os resultados de ICC foram classificados em “fracos” (ICC<0,4), “moderados” (0,4≤ICC<0,75) e “excelentes” (ICC≥0,75) (Shrout and Fleiss, 1979). Ainda, foram calculados: o erro padrão de medida (*standard error of measurement* – SEM); a mínima mudança detectável (*minimal detectable change* – MDC), todos expressos pela unidade de medida testada (no presente estudo, as variáveis contínuas são medidas em segundos). O SEM é a medida da reprodutibilidade absoluta, e expressa a variabilidade ao redor da medida inerente ao erro, calculada pela fórmula  $SEM = dp \sqrt{(1-ICC)}$ , onde dp é o desvio padrão do conjunto de resultados observados (Bruton et al., 2000). A MDC é considerada a mudança mínima que não se deve à chance de variação da medida, calculada pela fórmula  $MDC = \text{escore-z} \times dp \times \sqrt{(2(1-ICC))}$  (Haley and Fragala-Pinkham, 2006).

### 2.3 RESULTADOS

Foram avaliados 33 indivíduos, 18 do sexo feminino e 15 masculino, com idade média de 43,7±13,4 anos, tempo de diagnóstico 11,1±7,9 anos e moda da EDSS de 1. Todos os pacientes eram independentes para a realização de suas atividades de vida diária, sendo que a maioria relatava fadiga (63,6%). Quanto à deambulação, a maioria dos pacientes que participaram do estudo (73%) eram independentes para deambular em superfícies niveladas e desniveladas segundo a FAC (Tabela 1).

Tabela 1 – Caracterização da Amostra.

Características		n	%	Média (dp)
Gênero	Feminino	18	55%	-
	Masculino	15	45%	-

Idade (anos)		-	-	43,7 ( $\pm$ 13,4)
Tempo de diagnóstico (anos)		-	-	11,1 ( $\pm$ 7,9)
Faz acompanhamento fisioterapêutico?	Sim	7	21%	-
	Não	26	79%	-
Realiza atividade física?	Sim	18	55%	-
	Não	15	45%	-
Índice de Barthel	Totalmente Independente (=100)	15	45%	-
	Independente (>80)	18	55%	-
Escala de severidade da fadiga	Com fadiga ( $\geq$ 28)	21	63,6%	-
	Sem fadiga (<28)	12	36,4%	-
Escala de deambulação funcional	Independente em superfícies niveladas e desniveladas (nível 6)	24	73%	-
	Independente em superfícies de mesmo nível (nível 5)	4	12%	-
	Dependente de supervisão (nível 4)	2	6%	-
	Dependente nível 1 (3)	3	9%	-
Escala Expandida do Estado de Incapacidade*	0	2	6%	-
	1	7	23%	-
	1,5	2	6%	-
	3	6	19%	-
	3,5	7	23%	-
	4	1	3%	-
	4,5	2	6%	-
	5	3	10%	-
	6	1	3%	-
Altura do pé da cadeira	46 cm	10	30%	-
	45 cm	5	15%	-
	44 cm	11	33%	-
	43 cm	2	6%	-
	42 cm	5	15%	-

\* 31 Pacientes responderam o questionário quanto a EDSS, 2 pacientes deixaram em branco a resposta.



Em média, na primeira avaliação do A1, os pacientes executaram o TSLCV em  $15,0s \pm 7,1s$  e na primeira avaliação do A2 em  $14,9s \pm 6,8s$ . Na segunda avaliação do A1, o tempo de execução médio foi de  $15,4s \pm 7,0s$  (Tabela 2).

Os excelentes valores de ICC, associados aos baixos valores de SEM e MDC, confirmam a reprodutibilidade inter e intra-avaliador que do TSLCV executado de forma remota (Tabela 2).

Tabela 2 – Resultados da Concordância das Avaliações no TSLCV.

		Média e dp (s)	ICC	ICC 95%	Valor p	SEM (s)	MDC (s)
Inter-avaliador	A1	15,0±7,1	0,993	0,986 - 0,996	<0,001	0,6	1,6
	A2	14,9±6,8					
Intra-avaliador	A1	15,0±7,1	0,962	0,925 - 0,981	<0,001	1,4	3,8
	A1	15,4±7,0					

## 2.4 DISCUSSÃO

Este estudo foi o primeiro a investigar a reprodutibilidade do TSLCV, realizado de forma remota e síncrona, com pacientes portadores de EM do tipo SR. Os resultados mostraram excelente confiabilidade intra e interavaliador (Tabela 2), demonstrada pelos altos valores de ICC e baixos valores de SEM e MDC.

Quanto a confiabilidade intra-avaliador do TSLCV, vários estudos demonstraram resultados semelhantes aos nossos, embora tenham sido conduzidos com diferentes tipos de pacientes, diversos tamanhos de cadeiras e diferentes intervalos entre avaliações (Mong *et al.*, 2010; Wang *et al.*, 2012; Paul *et al.*, 2012; Khuna *et al.*, 2019; Van Cappellen-Van Maldegem *et al.*, 2022).

No estudo de Mong *et al.* (2010), os autores testaram a confiabilidade do TSLCV com 8 avaliadores distintos, em uma amostra de 12 participantes com AVC, utilizando uma cadeira de 43 cm de altura e 47,5 cm de profundidade, sem apoio de braços. Nesse estudo, os autores encontraram valor de ICC entre 0,970 (avaliadores F e G) e 0,976 (avaliadores B e C), também demonstrando excelente confiabilidade intra-avaliador do TSLCV, assim como o presente estudo.

Duncan *et al.* (2011), avaliaram 86 indivíduos com Doença de Parkinson (DP) idiopática com mais de 40 anos, com intervalo de uma semana. A altura da cadeira

da cadeira sem apoio de braço era de 43 cm. E mostrou excelente confiabilidade intra-avaliador do TSLCV, embora com valores inferiores de ICC (ICC=0,76). Paul *et al.* (2012), também avaliaram a confiabilidade intra-avaliador do TSLCV em pacientes com DP idiopática (n=31) com 40 anos e capacidade de deambulação independente, com um intervalo de uma semana, e encontraram ICC de 0,97 e SEM de 0,6. Quando avaliaram apenas os pacientes sem discinesia incapacitante (n=25), encontraram ICC de 0,99 e SEM de 0,5, demonstrando excelente confiabilidade do teste nesses pacientes. Com isso, ambos estudos corroboram com o nosso estudo, quanto aos seus resultados, apresentando excelente confiabilidade, porém divergem quanto ao intervalo entre avaliações, de uma semana, ao invés de 24-28 horas, utilizadas no presente estudo.

Wang *et al.* (2012) avaliaram 22 crianças com diplegia espástica, encontrando valor de ICC de 0,99, SEM de 0,02 rep/seg e MDC de 0,06 rep/seg, quando utilizada a média de 3 tentativas e ICC de 0,97, SEM de 0,04 rep/seg e MDC de 0,11 rep/seg, quando utilizada apenas a primeira tentativa. Com base nesses resultados, os autores concluíram que o TSLCV tem excelente confiabilidade intra-avaliador. As principais diferenças do estudo de Wang *et al.* (2012) em relação ao nosso estudo foram as características da cadeira (de altura ajustável para flexão de quadril de 90° e 105° de joelho) e o intervalo entre as avaliações (de dois dias). Apesar disso, o mesmo corrobora com o presente estudo devido ao excelente valor de ICC encontrado.

Resultados semelhantes também foram encontrados por Khuna *et al.* (2019), em 88 participantes ambulatoriais com Lesão Medular, avaliados com uma semana de diferença, alocados em 4 grupos que se diferenciavam pelo posicionamento de braço durante a execução do TSLCV, utilizando uma cadeira padrão sem apoio para os braços, com o paciente posicionado com flexão de quadril de 90° e os pés apoiados no chão com os calcanhares a 10 cm atrás dos joelhos. Os autores encontraram excelentes valores de ICC para cada situação avaliada: braços posicionados sobre um dispositivo de caminhada (n=30), com avaliador experiente (ICC=1,000) e com avaliador iniciante (ICC=0,998); braços posicionados sobre os joelhos (n=21), com avaliador experiente (ICC=0,999) e com avaliador iniciante (ICC=0,999); braços posicionados ao lado do corpo (n=20), com avaliador experiente (ICC=0,999) e com avaliador iniciante (ICC=0,999); braços cruzados à

frente do peito (n=20), com avaliador experiente (ICC=1,000) e com avaliador iniciante (ICC=1,000).

Também quanto a confiabilidade teste-reteste do TSLCV, Khuna *et al.* (2019) encontraram ICC variando de 0,956 a 0,989; SEM variando de 0,55s a 1,09s; e MDC variando de 1,53s a 3,01s, conforme as diferentes situações avaliadas. Os autores concluem que o TSLCV apresenta excelente confiabilidade, independente da experiência de avaliadores, para os quatro posicionamentos diferentes dos braços. Demonstrando, então, resultados que concordam com o presente estudo.

Northgraves *et al.* (2016) avaliaram 35 indivíduos entre 30 e 75 anos, utilizando uma cadeira de plástico de 40 cm de altura e 39 de profundidade, com os braços cruzados à frente do peito. Os resultados mostraram excelente confiabilidade teste-reteste, com ICC de 0,96, SEM de 0,58s, e MDC<sub>95</sub> de 1,60s. Apesar desses resultados, segundo os próprios autores, houve considerável variabilidade de desempenho individual.

Petersen *et al.* (2017) investigaram a confiabilidade teste-reteste do TSLCV em 22 pessoas com DP, utilizando uma cadeira sem braço de 47,5 cm de altura, com intervalo de 6 a 8 dias entre uma avaliação e outra. Os autores encontraram ICC de 0,74 e MDC<sub>95</sub> de 10,3s. Apesar da moderada confiabilidade teste-reteste, o MDC<sub>95</sub> foi muito alto, contrastando com nosso estudo, que encontrou baixo MDC.

No que se refere a confiabilidade inter-avaliador do TSLCV, nossos resultados demonstraram excelente confiabilidade, sendo corroborados por outros estudos (Mong *et al.*, 2010; Duncan *et al.*, 2011; Wang *et al.*, 2012; Khuna *et al.*, 2019).

Mong *et al.* (2010) e Duncan *et al.* (2011) encontraram valores de ICC de 0,99, evidenciando a excelente confiabilidade inter-avaliador do TSLCV. Resultados semelhantes foram encontrados por Wang *et al.* (2012), que avaliaram 108 crianças com diplegia espástica, apresentaram ICC de 0,95, também demonstrando excelente confiabilidade inter-avaliador. No estudo de Khuna *et al.* (2019), os valores de ICC para a confiabilidade inter-avaliador variaram de 0,998 a 1,000, quando avaliadas as quatro diferentes situações de execução do TSLCV: com os braços sobre o dispositivo de marcha, com os braços posicionados sobre os joelhos; com os braços ao lado do corpo; com os braços cruzados a frente do peito.

A excelente reprodutibilidade encontrada em nosso estudo contribui para a prática clínica, quando em certas situações se faz necessário avaliar a força

muscular do paciente de EM do tipo SR de forma remota e síncrona, em uma teleconsulta. Além disso demonstra valores de SEM e MDC, que também trazem contribuições interessantes para a prática clínica. O profissional que irá aplicar o TSLCV em seu paciente, pré e pós-intervenção, deve estar ciente que podem existir diferenças entre os tempos de execução do teste que são referentes ao teste em si, e não as mudanças nas características físicas do paciente. O SEM, é considerado um erro no teste, como por exemplo, um início ou término da contagem no tempo errado ou ainda atrasos devido a velocidade da própria internet. O MDC, que corresponde a mínima mudança detectável no tempo de execução do teste, mostra o valor a partir do qual pode-se atribuir uma mudança de fato na performance do paciente. Por exemplo, imagine um paciente portador de EM do tipo SR que em sua avaliação inicial com aplicação do TSLCV remoto e síncrono, tenha obtido 18s. Após algum tempo de intervenção, esse mesmo paciente é reavaliado, com o mesmo teste e pelo mesmo avaliador, obtendo 10s. A diferença de 8s entre pós e pré-intervenção não significa exatamente uma melhora do paciente, pois como MDC intra-avaliador é de 3,8s, a melhora real do paciente é de 4,2s. Esse tipo de informação ajuda o fisioterapeuta a conhecer de fato o quanto sua intervenção está impactando na melhora do paciente.

Entre as limitações encontradas no presente estudo, podem ser citados os problemas relacionados com a conexão de internet. O aplicativo WhatsApp foi escolhido para realizar as avaliações devido a sua ampla utilização, diminuindo os problemas de manejo por parte dos pacientes. Entretanto, até o momento das avaliações, o aplicativo não disponibilizava chamadas pelo computador. Com isso a conexão de internet era feita através de sinal 3G ao invés de cabo, o que gera instabilidade na conexão. Entendemos que o ideal seria realizar as avaliações através de um aplicativo compatível com microcomputadores, conectando-os à rede através de cabo, tanto o avaliador, quanto o paciente, diminuindo as interferências de sinais nas vídeo-chamadas. Outra limitação encontrada, só que agora referente ao paciente e ao intervalo entre avaliações, foi a sensação de calor. As avaliações ocorreram no verão do Hemisfério Sul, e devido a altas temperaturas existe uma tendência dos pacientes de EM apresentarem maior fadiga e queixas de menor força muscular, podendo influenciar na execução do TSLCV. Quanto a aplicação do TSLCV, outra limitação encontrada foi não existir uma padronização quanto a

característica da cadeira utilizada, podendo ser alta para alguns pacientes, ou baixa para outros pacientes.

## 2.5 CONCLUSÃO

O Teste de Sentar e Levantar de Cinco Vezes (TSLCV), executado de forma remota e síncrona, em pacientes com esclerose múltipla, é confiável, apresentando excelente reprodutibilidade inter e intra-avaliador, dada a partir dos altos valores de ICC e baixos valores de SEM e MDC.

## Financiamento

Esta pesquisa não recebeu nenhuma concessão específica de nenhuma agência de financiamento.

## 2.6 REFERÊNCIAS

- Barros, G., Vilela Junior, G., Stockler, S., Duvalier, A., 2009. AVALIAÇÃO E VALIDAÇÃO DA ESCALA BARTHEL PARA A LÍNGUA PORTUGUESA FALADA NO BRASIL 1, 1.
- Brasil, Resolução nº515, de 20 Março de 2020. **Diário Oficial da União**, Brasília, v. 158, n. 56, p. 184, 23 mar. 2020. Seção 1, pt. 1
- Browne, P., Chandraratna, D., Angood, C., Tremlett, H., Baker, C., Taylor, B.V., Thompson, A.J., 2014. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. *Neurology* 83, 1022–1024. <https://doi.org/10.1212/WNL.0000000000000768>
- Bruton, A., Conway, J.H., Holgate, S.T., 2000. Reliability: What is it, and how is it measured? *Physiotherapy* 86, 94–99. [https://doi.org/10.1016/S0031-9406\(05\)61211-4](https://doi.org/10.1016/S0031-9406(05)61211-4)
- Carvalho, R.B. de M., Ferreira, K.R., Modesto, F.C., 2020. A Fisioterapia Digital em Oncoginecologia durante a Pandemia de Covid-19. *Revista Brasileira de Cancerologia* 66, 1–3. <https://doi.org/10.32635/2176-9745.RBC.2020v66nTemaAtual.1082>
- Chen, P., Mao, L., Nassis, G.P., Harmer, P., Ainsworth, B.E., Li, F., 2020. Coronavirus disease (COVID-19): The need to maintain regular physical activity while taking precautions. *J Sport Health Sci* 9, 103–104. <https://doi.org/10.1016/j.jshs.2020.02.001>
- Csuka, M., McCarty, D.J., 1985. Simple method for measurement of lower extremity muscle strength. *Am J Med* 78, 77–81. [https://doi.org/10.1016/0002-9343\(85\)90465-6](https://doi.org/10.1016/0002-9343(85)90465-6)
- Duncan, R.P., Leddy, A.L., Earhart, G.M., 2011. Five times sit-to-stand test performance in Parkinson’s disease. *Arch Phys Med Rehabil* 92, 1431–1436. <https://doi.org/10.1016/j.apmr.2011.04.008>
- Elord, C., Corrêa, F.I., Pereira, G.S., Silva, S.M., Corrêa, J.C., 2020. Translation into Brazilian Portuguese, cross-cultural adaptation, reliability and validation of the

- Functional Ambulation Classification for the categorization of ambulation following a stroke in a clinical setting. *Rev Neurol* 70, 365–371.  
<https://doi.org/10.33588/rn.7010.2019400>
- Haley, S.M., Fragala-Pinkham, M.A., 2006. Interpreting change scores of tests and measures used in physical therapy. *Phys Ther* 86, 735–743.  
<https://doi.org/10.1093/ptj/86.5.735>
- Jørgensen, M., Dalgas, U., Wens, I., Hvid, L.G., 2017. Muscle strength and power in persons with multiple sclerosis - A systematic review and meta-analysis. *J Neurol Sci* 376, 225–241. <https://doi.org/10.1016/j.jns.2017.03.022>
- Khuna, L., Thaweewannakij, T., Wattanapan, P., Amatachaya, P., Amatachaya, S., 2019. Five times sit-to-stand test for ambulatory individuals with spinal cord injury: a psychometric study on the effects of arm placements. *Spinal Cord* 58, 1–9. <https://doi.org/10.1038/s41393-019-0372-3>
- Kim, M.J., Yabushita, N., Kim, M.K., Nemoto, M., Seino, S., Tanaka, K., 2010. Mobility performance tests for discriminating high risk of frailty in community-dwelling older women. *Archives of gerontology and geriatrics* 51, 192–198.  
<https://doi.org/10.1016/j.archger.2009.10.007>
- Koo, T.K., Li, M.Y., 2016. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. *J Chiropr Med* 15, 155–163.  
<https://doi.org/10.1016/j.jcm.2016.02.012>
- Møller, A.B., Bibby, B.M., Skjerbæk, A.G., Jensen, E., Sørensen, H., Stenager, E., Dalgas, U., 2012. Validity and variability of the 5-repetition sit-to-stand test in patients with multiple sclerosis. *Disabil Rehabil* 34, 2251–2258.  
<https://doi.org/10.3109/09638288.2012.683479>
- Mong, Y., Teo, T.W., Ng, S.S., 2010. 5-repetition sit-to-stand test in subjects with chronic stroke: reliability and validity. *Arch Phys Med Rehabil* 91, 407–413.  
<https://doi.org/10.1016/j.apmr.2009.10.030>
- Multiple Sclerosis International Federation, 2013. *Atlas of MS 2013: Mapping multiple sclerosis around the world*. Multiple Sclerosis International Federation, London.
- Ng, S.S.M., Cheung, S.Y., Lai, L.S.W., Liu, A.S.L., Ieong, S.H.I., Fong, S.S.M., 2015. Five Times Sit-To-Stand test completion times among older women: Influence of seat height and arm position. *J Rehabil Med* 47, 262–266.  
<https://doi.org/10.2340/16501977-1915>
- Ng, S.S.M., Cheung, S.Y., Lai, L.S.W., Liu, A.S.L., Ieong, S.H.I., Fong, S.S.M., 2013. Association of seat height and arm position on the five times sit-to-stand test times of stroke survivors. *Biomed Res Int* 2013, 1–7.  
<https://doi.org/10.1155/2013/642362>
- Northgraves, M.J., Hayes, S.C., Marshall, P., Madden, L.A., Vince, R.V., 2016. The test-retest reliability of four functional mobility tests in apparently healthy adults. *Isokinetics and Exercise Science* 24, 171–179.  
<https://doi.org/10.3233/IES-160614>
- Paul, S.S., Canning, C.G., Sherrington, C., Fung, V.S.C., 2012. Reproducibility of measures of leg muscle power, leg muscle strength, postural sway and mobility in people with Parkinson's disease. *Gait Posture* 36, 639–642.  
<https://doi.org/10.1016/j.gaitpost.2012.04.013>
- Petersen, C., Steffen, T., Paly, E., Dvorak, L., Nelson, R., 2017. Reliability and Minimal Detectable Change for Sit-to-Stand Tests and the Functional Gait

- Assessment for Individuals With Parkinson Disease. *J Geriatr Phys Ther* 40, 223–226. <https://doi.org/10.1519/JPT.000000000000102>
- Roldán-Jiménez, C., Bennett, P., Cuesta-Vargas, A.I., 2015. Muscular Activity and Fatigue in Lower-Limb and Trunk Muscles during Different Sit-To-Stand Tests. *PLoS One* 10, 1–12. <https://doi.org/10.1371/journal.pone.0141675>
- Shrout, P.E., Fleiss, J.L., 1979. Intraclass correlations: uses in assessing rater reliability. *Psychol Bull* 86, 420–428. <https://doi.org/10.1037//0033-2909.86.2.420>
- Silva, P.F.S., Quintino, L.F., Franco, J., Faria, C.D.C.M., 2014. Measurement properties and feasibility of clinical tests to assess sit-to-stand/stand-to-sit tasks in subjects with neurological disease: a systematic review. *Brazilian Journal of Physical Therapy* 18, 99–110. <https://doi.org/10.1590/S1413-35552012005000155>
- Simmonds, M.J., Olson, S.L., Jones, S., Hussein, T., Lee, C.E., Novy, D., Radwan, H., 1998. Psychometric characteristics and clinical usefulness of physical performance tests in patients with low back pain. *SPINE* 23, 2412–2421. <https://doi.org/10.1097/00007632-199811150-00011>
- Toledo, F.O., Junior, W.M., Speciali, J.G., Sobreira, C.F.D.R., 2011. PND66 Cross-Cultural Adaptation and Validation of the Brazilian Version of the Fatigue Severity Scale (FSS). *Value in Health* 14, A329–A330. <https://doi.org/10.1016/j.jval.2011.08.532>
- van Cappellen-van Maldegem, S.J.M., Hoedjes, M., Seidell, J.C., van de Poll-Franse, L.V., Buffart, L.M., Mols, F., Beijer, S., 2022. Self-performed Five Times Sit-To-Stand test at home as (pre-)screening tool for frailty in cancer survivors: Reliability and agreement assessment. *J Clin Nurs*. <https://doi.org/10.1111/jocn.16299>
- Wallmann, H.W., Evans, N.S., Day, C., Neelly, K.R., 2013. Interrater Reliability of the Five-Times-Sit-to-Stand Test. *Home Health Care Management & Practice* 25, 13–17. <https://doi.org/10.1177/1084822312453047>
- Walter, S.D., Eliasziw, M., Donner, A., 1998. Sample size and optimal designs for reliability studies. *Stat Med* 17, 101–110. [https://doi.org/10.1002/\(sici\)1097-0258\(19980115\)17:1<101::aid-sim727>3.0.co;2-e](https://doi.org/10.1002/(sici)1097-0258(19980115)17:1<101::aid-sim727>3.0.co;2-e)
- Walton, C., King, R., Rechtman, L., Kaye, W., Leray, E., Marrie, R.A., Robertson, N., La Rocca, N., Uitdehaag, B., van der Mei, I., Wallin, M., Helme, A., Angood Napier, C., Rijke, N., Baneke, P., 2020. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. *Mult Scler* 26, 1816–1821. <https://doi.org/10.1177/1352458520970841>
- Wang, T.-H., Liao, H.-F., Peng, Y.-C., 2012. Reliability and validity of the five-repetition sit-to-stand test for children with cerebral palsy. *Clin Rehabil* 26, 664–671. <https://doi.org/10.1177/0269215511426889>

### 3 ANEXOS

#### 3.1 ANEXO A – Normas da revista Multiple Sclerosis and Related Disorders

##### 3.1.1 Description

**Multiple Sclerosis** is an area of ever expanding research and escalating publications. *Multiple Sclerosis and Related Disorders* is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the **central nervous system**. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues. One section of the journal will focus on teaching, written to enhance the practice of community and academic neurologists involved in the care of MS patients. Summaries of key articles written for a lay audience will be provided as an on-line resource.

A team of four chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.

The journal will publish the following types of articles: Reviews; Original Research Articles; Editorials; Comment; Clinical Trial papers; Letter to the Editors; Case Reports; Book reviews; News. The [submission](#) of an on-line summary of selected papers of relevance for lay audience, Teaching Lessons and supporting images and datasets is also encouraged.

##### 3.1.2 Audience

All branches of neuroscience: clinical neurologists, neurophysiologists, geneticists, psychologist, molecular biologists, MRI and allied imaging specialists, immunologists, major pharmaceutical companies, ethical and legal specialists, MS specialist nurses, drug trial nurses.



### **3.1.3 Guide for authors**

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article. To find out more, please visit the Preparation section below.

#### 3.1.3.1 Introduction

##### *3.1.3.1.1 Types of article*

##### **Original Research Articles**

Full length research papers will not normally be more than 3500 words in length from the Introduction through the Discussion section and will preferably be shorter. Submission of a paper to Multiple Sclerosis and Related Disorders will be held to imply that it represents original research not previously published (except in the form of an abstract or preliminary report), that it is not being considered for publication elsewhere, and that if accepted by Multiple Sclerosis and Related Disorders it will not be published elsewhere in the same form in any language without the consent of the Publisher. Major papers of topical content will be given priority in publication.

##### *Book Reviews*

These are normally submitted by the Book Review Editors, but they welcome suggestions of books for review.

##### *Case Reports*

Please note we are no longer accepting case reports as such. These are now incorporated under 'Correspondence?'. Please refer to the section below

##### *Correspondence*

The Editors will consider for publication Correspondence, Editorials, Letters or Short Reports (including Case Reports) that illustrate important points. These should not

exceed 1000 words in length, have a title page, a summary of about 100 words and up to 10 references, one figure and one table. The word length restriction is not rigid and, in the case of Case Reports only, if the authors wish to write a detailed discussion there will be no limit on length unless advised otherwise by the reviewers.

#### *Clinical Trial papers*

Manuscripts detailing the results of clinical trials in MS and related disorders are encouraged. The trial methodology should account for all screened participants, and analyses should observe an intention-to-treat model where appropriate. All sources of funding for the study must be disclosed, and the involvement of the study sponsor must be detailed. Clinical trial manuscripts should be a maximum of 3500 words.

#### *Review Articles*

Review papers are normally 4000-5000 words in total. Authors are advised to consult one of the Editors with an outline before submitting a review.

#### *3.1.3.1.2 Contact details for submission*

Authors may send queries concerning the submission process, manuscript status, or journal procedures to our [Support Centre](#)

#### *3.1.3.1.3 Submission checklist*

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

*Manuscript:*

- Include Keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

*Graphical Abstracts / Highlights files* (where applicable)

*Supplemental files* (where applicable)

## Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#).

## 3.1.3.2 Before you begin

3.1.3.2.1 *Ethics in publishing*

Please see our information on [Ethics in publishing](#).

3.1.3.2.2 *Studies in humans and animals*

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association](#) (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the [Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals](#) and aim for the inclusion of representative human populations (sex, age and

ethnicity) as per those recommendations. The terms [sex and gender](#) should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARRIVE guidelines](#) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](#), or the National Research Council's [Guide for the Care and Use of Laboratory Animals](#) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

*Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders* The guide, reported here, is intended to act as a checklist to aid both authors and referees of manuscripts, just as the Consolidated Standards of Reporting Trials (CONSORT) guidelines are a compulsory part of reporting clinical trials.

Please click [here](#) for the [checklist](#) and the [complete article](#) by Sandra Amor and David Baker.

#### *3.1.3.2.3 Informed consent and patient details*

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the [Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals](#). Unless you have written permission from the patient (or, where applicable, the next of kin), the personal

details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

#### *3.1.3.2.4 Declaration of interest*

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patente applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double anonymized) or the manuscript file (if single anonymized). If there are no interests to declare then please state this: 'Declarations of interest: none'. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](#).

#### *3.1.3.2.5 Submission declaration and verification*

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see '[Multiple, redundant or concurrent publication](#)' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright holder. To verify originality, your article may be checked by the originality detection service [Crossref Similarity Check](#).

#### *Preprints*

Please note that [preprints](#) can be shared anywhere at any time, in line with Elsevier's [sharing policy](#). Sharing your preprints e.g. on a preprint server will not count as prior publication (see '[Multiple, redundant or concurrent publication](#)' for more information).

#### *3.1.3.2.6 Use of inclusive language*

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

#### *3.1.3.2.7 Author contributions*

For transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. [More details and an example.](#)

#### *3.1.3.2.8 Changes to authorship*

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made **Only before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must

receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that They agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

#### *3.1.3.2.9 Clinical trial results*

In line with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings) is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.

#### *Reporting clinical trials*

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The [CONSORT checklist and template flow diagram](#) are available online.

#### *Registration of clinical trials*

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with [International Committee of Medical Journal Editors](#) recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns

human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

#### *Article transfer servisse*

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. [More information](#).

#### *3.1.3.2.10 Copyright*

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' ([more information](#)). Permitted third party reuse of gold open access articles is determined by the author's choice of [user license](#).



### ***Author rights***

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

#### *Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals

#### *3.1.3.2.11 Role of the funding source*

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

#### *3.1.3.2.12 Open access*

Please visit our [Open Access page](#) for more information.

#### *Elsevier Researcher Academy*

[Researcher Academy](#) is a free e-learning platform designed to support early and mid career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

#### *Language (usage and editing services)*

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's Author Services.

### 3.1.3.2.13 *Submission*

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

#### *Submit your article*

Please submit your article via <https://www.editorialmanager.com/msard/default.aspx>

#### *Suggesting reviewers*

Please submit the names and institutional e-mail addresses of several potential reviewers.

You should not suggest reviewers who are colleagues, or who have co-authored or collaborated with you during the last three years. Editors do not invite reviewers who have potential competing interests with the authors. Further, in order to provide a broad and balanced assessment of the work, and ensure scientific rigor, please suggest diverse candidate reviewers who are located in different countries/ regions from the author group. Also consider other diversity attributes e.g. gender, race and ethnicity, career stage, etc. Finally, you should not include existing members of the journal's editorial team, of whom the journal are already aware.

Note: the editor decides whether or not to invite your suggested reviewers.

### 3.1.3.3 Preparation

#### 3.1.3.3.1 *Queries*

For questions about the editorial process (including the status of manuscripts under review) or for technical support on submissions, please visit our [Support Center](#).

#### 3.1.3.3.2 *New submissions*

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

### *References*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

### *Formatting requirements*

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

Divide the article into clearly defined sections.

### *Figures and tables embedded in text*

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

#### *3.1.3.3 Peer review*

This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has no interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. [More information on types of peer review](#).

#### *3.1.3.3.4 Revised submissions*

##### *Use of word processing software*

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts ([see also the Guide to Publishing with Elsevier](#)). See also the section on Electronic artwork. To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

#### *3.1.3.3.5 Article structure*

##### *Subdivision - numbered sections*

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

##### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

### *Material and methods*

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

### *Results*

Results should be clear and concise.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

### *Appendices*

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

#### *3.1.3.3.6 Essential title page information*

**Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

**Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

**Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**

**Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

#### *3.1.3.3.7 Highlights*

Highlights are mandatory for this journal as they help increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: [example Highlights](#).

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

#### *3.1.3.3.8 Abstract*

A structured abstract that includes the headings: Background, Methods, Results, and Conclusion is required. The abstract must not exceed 500 words. **Background.** The background should provide a brief and concise description of the background and

reason for the study citing relevant literature overview, and a clear statement of hypothesis, and study objectives. The introduction should not be an exhaustive review of the literature. **Methods.** This section provides a concise description of the procedural, experimental, and statistical methods in sufficient detail to allow other investigators to reproduce the study. **Results.** State concisely the results of the study. **Conclusion.** Briefly summarize the major conclusions of the investigation.

#### Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site. Authors can make use of Elsevier's [Illustration Services](#) to ensure the best presentation of their images and in accordance with all technical requirements.

#### 3.1.3.3.9 Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

#### *Abbreviations*

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

### *Acknowledgements*

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

### *Formatting of funding sources*

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, it is recommended to include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### *Math formulae*

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g.,  $X/Y$ . In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

### *Footnotes*

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be



used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

### 3.1.3.3.10 *Artwork*

#### *Electronic artwork*

##### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files.

A detailed [guide on electronic artwork](#) is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

##### *Formats*

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

**Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

### *Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. [Further information on the preparation of electronic artwork.](#)

### *Illustration services*

[Elsevier's Author Services](#) offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

### *Figure captions*

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

#### *3.1.3.3.11 Tables*

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number

tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

### 3.1.3.3.12 *References*

#### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

#### *Reference management software*

This journal has standard templates available in key reference management packages EndNote <http://www.endnote.com/support/enstyles.asp> and Reference Manager <http://refman.com/support/rmstyles.asp>. Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

#### *Reference links*

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *Journal of Geophysical Research*, <https://doi.org/10.1029/2001JB000884>. Please note the format of such citations should be in the same style as all other references in the paper.

#### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

#### *Data references*

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

#### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

#### *Reference management software*

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#). Using citation plug-ins from these products, authors only need to select the appropriate journal template

when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. [More information on how to remove field codes from different reference management software.](#)

### *Reference formatting*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

### *Reference style*

Text: All citations in the text should refer to:

1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;
2. Two authors: both authors' names and the year of publication;
3. Three or more authors: first author's name followed by 'et al.' and the year of publication.

Citations may be made directly (or parenthetically). Groups of references can be listed either first alphabetically, then chronologically, or vice versa.

Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999)....  
Or, as demonstrated (Jones, 1999; Allan, 2000)... Kramer et al. (2010) have recently shown ...'

List: References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

Examples:

Reference to a journal publication:

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. *J. Sci. Commun.* 163, 51–59. <https://doi.org/10.1016/j.Sc.2010.00372>.

Reference to a journal publication with an article number:

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2018. The art of writing a scientific article. *Heliyon.* 19, e00205. <https://doi.org/10.1016/j.heliyon.2018.e00205>.

Reference to a book: Strunk Jr., W., White, E.B., 2000. *The Elements of Style*, fourth ed. Longman, New York.

Reference to a chapter in an edited book:

Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S., Smith, R.Z. (Eds.), *Introduction to the Electronic Age*. E Publishing Inc., New York, pp. 281–304.

Reference to a website:

Cancer Research UK, 1975. Cancer statistics reports for the UK. <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/> (accessed 13 March 2003).

Reference to a dataset:

[dataset] Oguro, M., Imahiro, S., Saito, S., Nakashizuka, T., 2015. Mortality data for Japanese oak wilt disease and surrounding forest compositions. *Mendeley Data*, v1. <https://doi.org/10.17632/xwj98nb39r.1>.

Reference to software:

Coon, E., Berndt, M., Jan, A., Svyatsky, D., Atchley, A., Kikinzon, E., Harp, D., Manzini, G., Shelef, E., Lipnikov, K., Garimella, R., Xu, C., Moulton, D., Karra, S., Painter, S., Jafarov, E., & Molins, S., 2020. *Advanced Terrestrial Simulator (ATS) v0.88 (Version 0.88)*. Zenodo. <https://doi.org/10.5281/zenodo.3727209>.

### *Journal abbreviations source*

Journal names should be abbreviated according to the [List of Title Word Abbreviations](#).

### 3.1.3.3.13 Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including [ScienceDirect](#). Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our [video instruction pages](#). Note: since video and Animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

### *Patient Details*

Every video submission must consist of high-resolution images and a consent form for publication for educational purposes signed by the patient see form, please see the **Patient Details** section below. The Editors reserve the right to ask for additional video/s or video modifications.

**Patient Details** Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in your paper. If you wish to include images of patients or case details in an Elsevier publication, you will need to adhere to the following requirements: In order to comply with data protection and privacy rules, each individual who appears in any video, recording, photograph or case report must be made aware in advance of the fact that such photographs are being taken or such video, recording or report is being made and of all of the purposes for which you wish to use them and that individual (or next of kin in the case of children) must give his/ her explicit written consent. If such consent is made subject to any conditions (for example, adopting measures to prevent personal

identification of the person concerned), Elsevier must be made aware of all such conditions. Written consents must be provided to Elsevier on request.

The author is responsible for obtaining all necessary consents from patients for (i) the performance of any medical procedure involved, as well as (ii) a release permitting our use of the relevant material. It is our insurers' preference that we do not have any direct contractual relationship with the patients themselves. Please download the Patient consent form [here](#)

#### *3.1.3.3.14 Data visualization*

Include interactive data visualizations in your publication and let your readers Interact and engage more closely with your research. Follow the instructions [here](#) to find out about available data visualization options and how to include them with your article.

#### *3.1.3.3.15 Supplementary material*

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

#### *3.1.3.3.16 Research data*

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.



Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

### *Data linking*

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

### *Mendeley Data*

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to use, open access repository. Before submitting your article, you can deposit the relevant datasets to Mendeley Data. Please include the DOI of the deposited dataset(s) in your main manuscript file. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

#### *Data statement*

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

#### 3.1.3.4 After acceptance

##### *Availability of accepted article*

This journal makes articles available online as soon as possible after acceptance. This concerns the Journal Pre-proofs (both in HTML and PDF format), which have undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but are not yet the definitive versions of record. A Digital Object Identifier (DOI) is allocated, thereby making it fully citable and searchable by title, author name(s) and the full text. The article's PDF also carries a disclaimer stating that it is an unedited article. Subsequent production stages will simply replace this version.

##### *3.1.3.4.1 Online proof correction*

To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

#### *3.1.3.4.2 Offprints*

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Author Services](#). Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

#### *3.1.3.5 Author inquiries*

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).